Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics and baseline disease characteristics (N = 18 patients)

From: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

Variable No. of patients (%)
Age, years; median (range) 53 (30–73)
Cutaneous primary 17 (94)
Unknown primary 1 (6)
Gender  
 Female 12 (67)
 Male 6 (33)
Performance status (ECOG)a  
 0 11 (61)
 1 7 (39)
Recurrent disease after prior surgery 15 (83)
Prior adjuvant HDIb 6 (33)
Presence of in-transit metastases 12 (67)
Estimated risk stage  
 IIIB 2 (11)
 IIIC 16 (89)
Tumor mutational status  
 BRAFV600 9 (50)
 NRASQ61 5 (28)
 Unknown 1 (5)
  1. aECOG: Eastern Cooperative Oncology Group; bHDI: high dose interferon-α